1 – 10 of 12
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Association of Annual N-Terminal Pro-Brain Natriuretic Peptide Measurements with Clinical Events in Patients with Asymptomatic Nonsevere Aortic Stenosis : A Post Hoc Substudy of the SEAS Trial
(
- Contribution to journal › Article
- 2016
-
Mark
Assessing optimal blood pressure in patients with asymptomatic aortic valve stenosis
(
- Contribution to journal › Article
- 2015
-
Mark
High sensitivity C reactive protein as a prognostic marker in patients with mild to moderate aortic valve stenosis during lipid-lowering treatment: an SEAS substudy.
(
- Contribution to journal › Article
- 2014
-
Mark
Incidence of Cancer and Mortality in Patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Trial.
(
- Contribution to journal › Article
- 2012
-
Mark
A risk score for predicting mortality in patients with asymptomatic mild to moderate aortic stenosis
(
- Contribution to journal › Article
-
Mark
Clinical Implications of Electrocardiographic Left Ventricular Strain and Hypertrophy in Asymptomatic Patients With Aortic Stenosis The Simvastatin and Ezetimibe in Aortic Stenosis Study
(
- Contribution to journal › Article
- 2011
-
Mark
Response to Letters Regarding Article, "Outcome of Patients With Low-Gradient "Severe" Aortic Stenosis and Preserved Ejection Fraction"
(
- Contribution to journal › Letter
-
Mark
Outcome of Patients With Low-Gradient "Severe" Aortic Stenosis and Preserved Ejection Fraction
(
- Contribution to journal › Article
- 2010
-
Mark
Observed and Predicted Reduction of Ischemic Cardiovascular Events in the Simvastatin and Ezetimibe in Aortic Stenosis Trial
(
- Contribution to journal › Article
-
Mark
Impact of Baseline Severity of Aortic Valve Stenosis on Effect of Intensive Lipid Lowering Therapy (from the SEAS Study)
(
- Contribution to journal › Article